Helix BioPharma Corp. Announces Regulatory Approval to Dose Patients in a Phase II Randomized Study of L-DOS47 With Vinorelbine and Cisplatin

    NEXT STORY
    Cannabis Science Issues First 2018 Guidance Report; 4/20 Court Date Set For Lawsuit Against San Joaquin County; Revenue Growth Through Acquisitions, Wholesale, and Retail Sales Channels All Multiply
    PREV STORY
    CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    In vitro Diagnostics Market is Forecast to Rise at 4.5% CAGR and Reach USD 87.11 Billion by 2026; Launch of Altostar Molecular Diagnostics Workflow by Altona Diagnostics Gmbh Will Support Growth, says Fortune Business Insights

    author_avatar
    NASDAQ Market News

    Summit Therapeutics to Present at the Biotech Showcase

    Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT THE BIOTECH ...

    author_avatar
    NASDAQ Market News

    Versartis Initiates Phase 3 Trial of Somavaratan in Japan for Children with Growth Hormone Deficiency Following Completion of Phase 2

    MENLO PARK, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused ...

    author_avatar
    NASDAQ Market News